Antibacterial agent 344
Antibacterial agent 344 is an antibacterial agent with potent biofilm inhibition (IC50 = 0.27 μM). Antibacterial agent 344 inhibits heme oxygenase (HemO), impairs iron homeostasis, virulence factor production, and motility. Antibacterial agent 344 synergizes with Ciprofloxacin (HY-B0356) and Tobramycin (HY-B0441), enhancing their efficacy and delaying the development of resistance. Antibacterial agent 344 improves bacterial-infected Galleria mellonella survival, and reduces bacterial load in mice wounds. Antibacterial agent 344 can be used for the research of Pseudomonas aeruginosa infections.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- 화학식: C18H14N4O3S2
- 분자량:398.46
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
Antibacterial agent 344 (Compound 4p) (0.125-2 μM; 16 h) reduces biofilm, elastase production and iron acquisition in Pseudomonas aeruginosa PAO1 in a concentration-dependent manner[1].
Antibacterial agent 344 binds to HemO protein with a Kd of 269.7 nM[1].
Antibacterial agent 344 shows antibiofilm activity against Pseudomonas aeruginosa PA0405, PA0319, PA0730, PA0209, and PA092 with IC50 values of 0.99-7.87 μM[1].
Antibacterial agent 344 shows synergistic effects of with Ciprofloxacin (HY-B0356) and Tobramycin (HY-B0441)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Antibacterial agent 344 (2 μM; topical; once daily; 9 days) reduces P. aeruginosa PAO1 bacterial load and accelerates wound healing in mouse wound infections when co-administered with ciprofloxacin or tobramycin, without causing detectable organ toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:monas aeruginosa wound infected BALB/c mice (female, 3-5 weeks old)[1]
-
Dosage:2 μM
-
Administration:topical; once daily; 9 days
-
Result:Reduced bacterial load by 2.10 log10 CFU compared to the control and 1.37 log10 CFU compared to ciprofloxacin monotherapy when combined with 0.0008 mg/mL Ciprofloxacin.
Accelerated wound healing compared to control and Ciprofloxacin monotherapy when combined with 0.0008 mg/mL ciprofloxacin.
Reduced bacterial load by 2.11 log10 CFU compared to the control and relative to Tobramycin monotherapy when combined with 0.002 mg/mL Tobramycin.
Accelerated wound healing compared to control and Tobramycin monotherapy when combined with 0.002 mg/mL tobramycin.
Caused no histopathological alterations in heart, liver, spleen, lung, or kidney tissues.
Caused no significant body weight changes.
Chemical Information
-
분자량 398.46
-
화학식 C18H14N4O3S2
-
SMILES
O=C(CN1N=NC(CSC2=NC3=C(S2)C=CC=C3)=C1)C4=CC=C(C(O)=C4)O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Antibacterial agent 344 Related Classifications
HY-183711 Related Classifications
Powered by Bioz
- Antibacterial agent 344
- Antibacterial agent344
- Antibacterial agent-344
- Bacterial
- Heme Oxygenase (HO)
- Pseudomonas aeruginosa PAO1
- Galleria mellonella
- elastase
- mouse wound infections
- heme iron acquisition
- biofilm formation
- HemO
- virulence factor production
- iron homeostasis
- Pseudomonas aeruginosa
- Inhibitor
- inhibitor
- inhibit